Trading Halt
Filed with ASX · · 2 pages · English
On 6ix: 6ix.com/news/trading-halt-1407
Trading in the securities of Chimeric Therapeutics Limited (‘CHM’) will be halted at the request of CHM, pending the release of an announcement by CHM. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Tuesday, 23 December 2025; or • the release of the announcement to the market. CHM’s request for a trading halt i
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- CDH17 granted FDA Orphan Drug Designation for Gastric Cancer
- Chimeric receives $4.5M R&D tax incentive
- 75% disease control observed in CHM CDH17 trial
- CHM CORE NK Combination Phase 1b trial update
- Pause in Trading
Later from Chimeric Therapeutics
- $8.4 M funding to drive CHM CDH17 and resignation of CMO
- Quarterly Activities/Appendix 4C Cash Flow Report
- Funding and EGM update
- Portfolio streamlined - return of CHM CLTX to City of Hope
- Half Year Report and Appendix 4D 31 December 2025
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics